Femasys’ (FEMY) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Femasys (NASDAQ:FEMY) in a research note released on Wednesday morning,Benzinga reports. They currently have a $12.00 target price on the stock.

Separately, Chardan Capital dropped their price target on Femasys from $10.00 to $8.00 and set a “buy” rating for the company in a report on Wednesday, November 13th.

Femasys Price Performance

Shares of Femasys stock opened at $1.04 on Wednesday. The firm has a market cap of $23.82 million, a P/E ratio of -1.28 and a beta of -2.83. The firm’s 50-day simple moving average is $1.14 and its 200-day simple moving average is $1.13. Femasys has a twelve month low of $0.73 and a twelve month high of $2.40. The company has a debt-to-equity ratio of 0.86, a quick ratio of 3.26 and a current ratio of 3.94.

Femasys (NASDAQ:FEMY) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.04). The company had revenue of $0.55 million for the quarter, compared to analyst estimates of $0.40 million. Femasys had a negative net margin of 1,435.77% and a negative return on equity of 141.49%. As a group, research analysts expect that Femasys will post -0.84 EPS for the current fiscal year.

Hedge Funds Weigh In On Femasys

A number of institutional investors have recently modified their holdings of the stock. CM Management LLC increased its holdings in shares of Femasys by 6.3% in the second quarter. CM Management LLC now owns 425,000 shares of the company’s stock valued at $484,000 after purchasing an additional 25,000 shares in the last quarter. Aljian Capital Management LLC acquired a new stake in shares of Femasys in the 3rd quarter valued at $27,000. XTX Topco Ltd raised its position in shares of Femasys by 123.9% during the third quarter. XTX Topco Ltd now owns 32,535 shares of the company’s stock worth $36,000 after acquiring an additional 18,004 shares during the last quarter. Finally, Geode Capital Management LLC lifted its stake in shares of Femasys by 9.2% during the third quarter. Geode Capital Management LLC now owns 206,483 shares of the company’s stock valued at $229,000 after acquiring an additional 17,473 shares during the period. 65.27% of the stock is owned by institutional investors.

About Femasys

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.